Effect of Sinovac on Survival in Intensive Care Unit
Effect of Inactivated COVID-19 Vaccine, Sinovac on Survival in Intensive Care Unit
1 other identifier
observational
96
1 country
1
Brief Summary
Effect of Inactivated COVID-19 Vaccine (Sinovac) on survival in intensive care unit, Single Center Experience
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2021
CompletedFirst Submitted
Initial submission to the registry
June 30, 2021
CompletedFirst Posted
Study publicly available on registry
July 9, 2021
CompletedJuly 9, 2021
June 1, 2021
1 month
June 30, 2021
June 30, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
survival data
If the patient dies, we have reached an outcome
30 days
Study Arms (2)
Vaccinated with sinovac
Vaccinated COVID-19 patients over 65 years consisted the study group
Unvaccinated
Unvaccinated patients over 65 years composed the control group
Eligibility Criteria
Patients admitted to our institution's intensive care unit (ICU) between 01 April 2021 and 15 May 2021 was enrolled to the study. Exclusion criteria was admissions to ICU due to reasons other than COVID-19, age younger than 18, continued admission at the end of enrolment date.
You may qualify if:
- Patients with covid 19 over the age of 65 who were admitted to the intensive care unit between 1 April 2021 and 15 May 2021
You may not qualify if:
- admissions to ICU due to reasons other than COVID-19, age younger than 65, continued admission at the end of enrolment date,
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sisli Hamidiye Etfal Research and Training Hospital
Istanbul, 34771, Turkey (Türkiye)
Related Publications (1)
Sevinc SA, Metin S, Basi NB, Ling J, Cinar AS, Oba S. Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival. Epidemiol Infect. 2022 Feb 9;150:e35. doi: 10.1017/S0950268822000267.
PMID: 35135644DERIVED
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- consultant doctor
Study Record Dates
First Submitted
June 30, 2021
First Posted
July 9, 2021
Study Start
April 1, 2021
Primary Completion
May 15, 2021
Study Completion
May 15, 2021
Last Updated
July 9, 2021
Record last verified: 2021-06